Previous 10 | Next 10 |
JanOne (NASDAQ: JAN ) +127% on acquiring worldwide license for treatment of Peripheral Arterial Disease. More news on: JanOne Inc., Sorrento Therapeutics, Inc., The Medicines Company, Stocks on the move, Read more ...
AnaptysBio, Inc. ( ANAB ) got slammed down 72% last Friday on news that its ATLAS Phase 2b Clinical Trial in moderate-to-severe atopic dermatitis failed to meet its primary endpoint. This kind of drop is typical for a failed biotech, and many of them drop to below their net cash value, at le...
Shares of Dermira (NASDAQ: DERM) , a dermatology-focused biopharmaceutical company, shot up in response to a potential competitor's clinical trial failure. The demise of AnaptysBio 's (NASDAQ: ANAB) experimental eczema treatment has lifted Dermira's stock price 22.1% higher as of 1:55 ...
Gainers: Leaf Group (NYSE: LEAF ) +40% . More news on: Leaf Group Ltd., Clovis Oncology, Inc., RAPT Therapeutics, Inc., Stocks on the move, Read more ...
AnaptysBio (NASDAQ: ANAB ) -73% after Q3 results and lead drug flunks dermatitis study. More news on: AnaptysBio, Inc., Therapix Biosciences Ltd., Red Lion Hotels Corporation, Stocks on the move, Read more ...
Thinly traded AnaptysBio (NASDAQ: ANAB ) craters 74% premarket on robust volume in response to its announcement that lead candidate etokimab failed to achieve the primary endpoint in a Phase 2b clinical trial, ATLAS , in patients with moderate-to-severe atopic dermatitis. Mo...
AnaptysBio (NASDAQ: ANAB ): Q3 GAAP EPS of -$1.15 in-line. More news on: AnaptysBio, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Topline Data From Etokimab ATLAS Phase 2b Clinical Trial in Moderate-to-Severe Atopic Dermatitis Failed to Meet Primary Endpoint Reported Positive Topline Data from Interim Analysis of GALLOP Phase 2 Clinical Trial of ANB019 Monotherapy in Moderate-to-Severe Generalized Pustular Psorias...
SAN DIEGO, Nov. 08, 2019 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced topline data from its ATLAS trial, a Phase 2b randomized...
A promising pipeline, collaborations with deep-pocketed partners, and adequate financing are some of the things investors look for in clinical-stage biopharma companies. AnaptysBio (NASDAQ: ANAB) offers most of those things, but has recently discovered that "promising pipeline" is a subjecti...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States 60 Degrees Pharmaceuticals Inc. (SXTP) rose 98.3% to $0.4878 on volume of 116,444,604 shares NVIDIA Corporation (NVDA) fell 0.2% to $120.8 on volume of 26,900,560 shares Serve Robotics Inc. (SERV) rose 61.2% to $4.2399 on volume of 25...
2024-05-10 18:15:02 ET Wells Fargo analyst issues BUY recommendation for ANAB on May 10, 2024 05:01PM ET. The previous analyst recommendation was Buy. ANAB was trading at $23.41 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current ana...
Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist; reiterating top-line data anticipated by year-end 2024 Enrollment ongoing for global Phase 2b trial to treat rheumatoid arthritis (RA) and global Phase 2 trial to treat ulcerative colit...